Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis

Ibrahim T. Aldoss, Tsewang Tashi, Wilson Gonsalves, Ranin K. Kalaiah, Xiang Fang, Peter T. Silberstein, Apar K. Ganti, Shanmuga Subbiah

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Metastatic pancreatic cancer is an incurable disease with dismal prognosis, ranging from 2 to 6. months. The role of chemotherapy for metastatic pancreatic cancer in very elderly patients (≥ 80 years) has not been well studied. Methods: We reviewed all cases of metastatic pancreatic cancer in patients aged ≥ 80 years in the Veterans Affairs Central Cancer Registry (VACCR) from 1995 to 2007. Four hundred and forty patients were identified. Type of therapy received, tumor grade, tobacco history, sex and race were noted. Overall survival was calculated by log rank and Kaplan-Meier analysis. Baseline co-morbid conditions were scored using the Charlson co-morbidity index score (CCIS), a validated measure of patient co-morbidity. Results: Among the 440 eligible patients in the analysis, the majority received no therapy (83%), while only 12% received chemotherapy alone. Multivariate analysis demonstrated that chemotherapy was associated with significant superior median overall survival (4.9. months, 95% CI 3.57-5.77) compared to no therapy (1.7. months, 95% CI 0.9-1.3) (HR = 0.41, p <0.0001). One-year survival was higher in patients receiving chemotherapy compared to patients who received no therapy (13% vs. 3%). Current smoking was associated with decreased median overall survival compared to past or never smoking status (1.18 vs. 1.63 and 1.57. months respectively, p = 0.0087). Conclusion: Although the majority of elderly patients with metastatic pancreatic cancer do not receive any treatment, chemotherapy in this patient population was associated with improved median overall survival. Further randomized studies are warranted to confirm this observation.

Original languageEnglish
Pages (from-to)209-214
Number of pages6
JournalJournal of Geriatric Oncology
Volume2
Issue number3
DOIs
StatePublished - Jul 2011

Fingerprint

Veterans
Pancreatic Neoplasms
Registries
Drug Therapy
Neoplasms
Survival
Smoking
Morbidity
Therapeutics
Kaplan-Meier Estimate
Tobacco
Multivariate Analysis
History

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology
  • Oncology

Cite this

Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis. / Aldoss, Ibrahim T.; Tashi, Tsewang; Gonsalves, Wilson; Kalaiah, Ranin K.; Fang, Xiang; Silberstein, Peter T.; Ganti, Apar K.; Subbiah, Shanmuga.

In: Journal of Geriatric Oncology, Vol. 2, No. 3, 07.2011, p. 209-214.

Research output: Contribution to journalArticle

Aldoss, Ibrahim T. ; Tashi, Tsewang ; Gonsalves, Wilson ; Kalaiah, Ranin K. ; Fang, Xiang ; Silberstein, Peter T. ; Ganti, Apar K. ; Subbiah, Shanmuga. / Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis. In: Journal of Geriatric Oncology. 2011 ; Vol. 2, No. 3. pp. 209-214.
@article{6fe58b620a994fa696729605eec378d3,
title = "Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis",
abstract = "Background: Metastatic pancreatic cancer is an incurable disease with dismal prognosis, ranging from 2 to 6. months. The role of chemotherapy for metastatic pancreatic cancer in very elderly patients (≥ 80 years) has not been well studied. Methods: We reviewed all cases of metastatic pancreatic cancer in patients aged ≥ 80 years in the Veterans Affairs Central Cancer Registry (VACCR) from 1995 to 2007. Four hundred and forty patients were identified. Type of therapy received, tumor grade, tobacco history, sex and race were noted. Overall survival was calculated by log rank and Kaplan-Meier analysis. Baseline co-morbid conditions were scored using the Charlson co-morbidity index score (CCIS), a validated measure of patient co-morbidity. Results: Among the 440 eligible patients in the analysis, the majority received no therapy (83{\%}), while only 12{\%} received chemotherapy alone. Multivariate analysis demonstrated that chemotherapy was associated with significant superior median overall survival (4.9. months, 95{\%} CI 3.57-5.77) compared to no therapy (1.7. months, 95{\%} CI 0.9-1.3) (HR = 0.41, p <0.0001). One-year survival was higher in patients receiving chemotherapy compared to patients who received no therapy (13{\%} vs. 3{\%}). Current smoking was associated with decreased median overall survival compared to past or never smoking status (1.18 vs. 1.63 and 1.57. months respectively, p = 0.0087). Conclusion: Although the majority of elderly patients with metastatic pancreatic cancer do not receive any treatment, chemotherapy in this patient population was associated with improved median overall survival. Further randomized studies are warranted to confirm this observation.",
author = "Aldoss, {Ibrahim T.} and Tsewang Tashi and Wilson Gonsalves and Kalaiah, {Ranin K.} and Xiang Fang and Silberstein, {Peter T.} and Ganti, {Apar K.} and Shanmuga Subbiah",
year = "2011",
month = "7",
doi = "10.1016/j.jgo.2011.02.003",
language = "English",
volume = "2",
pages = "209--214",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis

AU - Aldoss, Ibrahim T.

AU - Tashi, Tsewang

AU - Gonsalves, Wilson

AU - Kalaiah, Ranin K.

AU - Fang, Xiang

AU - Silberstein, Peter T.

AU - Ganti, Apar K.

AU - Subbiah, Shanmuga

PY - 2011/7

Y1 - 2011/7

N2 - Background: Metastatic pancreatic cancer is an incurable disease with dismal prognosis, ranging from 2 to 6. months. The role of chemotherapy for metastatic pancreatic cancer in very elderly patients (≥ 80 years) has not been well studied. Methods: We reviewed all cases of metastatic pancreatic cancer in patients aged ≥ 80 years in the Veterans Affairs Central Cancer Registry (VACCR) from 1995 to 2007. Four hundred and forty patients were identified. Type of therapy received, tumor grade, tobacco history, sex and race were noted. Overall survival was calculated by log rank and Kaplan-Meier analysis. Baseline co-morbid conditions were scored using the Charlson co-morbidity index score (CCIS), a validated measure of patient co-morbidity. Results: Among the 440 eligible patients in the analysis, the majority received no therapy (83%), while only 12% received chemotherapy alone. Multivariate analysis demonstrated that chemotherapy was associated with significant superior median overall survival (4.9. months, 95% CI 3.57-5.77) compared to no therapy (1.7. months, 95% CI 0.9-1.3) (HR = 0.41, p <0.0001). One-year survival was higher in patients receiving chemotherapy compared to patients who received no therapy (13% vs. 3%). Current smoking was associated with decreased median overall survival compared to past or never smoking status (1.18 vs. 1.63 and 1.57. months respectively, p = 0.0087). Conclusion: Although the majority of elderly patients with metastatic pancreatic cancer do not receive any treatment, chemotherapy in this patient population was associated with improved median overall survival. Further randomized studies are warranted to confirm this observation.

AB - Background: Metastatic pancreatic cancer is an incurable disease with dismal prognosis, ranging from 2 to 6. months. The role of chemotherapy for metastatic pancreatic cancer in very elderly patients (≥ 80 years) has not been well studied. Methods: We reviewed all cases of metastatic pancreatic cancer in patients aged ≥ 80 years in the Veterans Affairs Central Cancer Registry (VACCR) from 1995 to 2007. Four hundred and forty patients were identified. Type of therapy received, tumor grade, tobacco history, sex and race were noted. Overall survival was calculated by log rank and Kaplan-Meier analysis. Baseline co-morbid conditions were scored using the Charlson co-morbidity index score (CCIS), a validated measure of patient co-morbidity. Results: Among the 440 eligible patients in the analysis, the majority received no therapy (83%), while only 12% received chemotherapy alone. Multivariate analysis demonstrated that chemotherapy was associated with significant superior median overall survival (4.9. months, 95% CI 3.57-5.77) compared to no therapy (1.7. months, 95% CI 0.9-1.3) (HR = 0.41, p <0.0001). One-year survival was higher in patients receiving chemotherapy compared to patients who received no therapy (13% vs. 3%). Current smoking was associated with decreased median overall survival compared to past or never smoking status (1.18 vs. 1.63 and 1.57. months respectively, p = 0.0087). Conclusion: Although the majority of elderly patients with metastatic pancreatic cancer do not receive any treatment, chemotherapy in this patient population was associated with improved median overall survival. Further randomized studies are warranted to confirm this observation.

UR - http://www.scopus.com/inward/record.url?scp=79958728624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958728624&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2011.02.003

DO - 10.1016/j.jgo.2011.02.003

M3 - Article

VL - 2

SP - 209

EP - 214

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

IS - 3

ER -